More than 80% of NCEs are poorly soluble compounds, making solubilization a critical factor in the formulation stage of the drug development process. Overcoming this challenge using lipid nanoparticles is essential to move your drug product through the development pipeline. Conventional formulation technologies, while successful for numerous commercial drugs in oral tablets, oral liquids, and parenteral formulations, can pose obstacles when it comes to compatibility with excipients and processing conditions used in manufacturing.
Lipids used in drug development products have improved suitability and greater drug delivery efficiency. However, each Active Pharmaceutical Ingredient (API) presents various complications for nanosizing, such as unwanted toxicity and side effects, making it crucial to find the appropriate formulation technologies and strategies to help prevent unwanted side effects in clinical studies and in post launch marketed drugs. Lipid nanoparticles offer higher drug encapsulation efficiency; stability; ease of preparation; biocompatibility; non-immunogenicity; and controlled release, tissue targeting, and maximum drug entrapment efficiency. Discover how a CDMO partner with proven success in creating formulations to overcome poor solubility can take your product to market on schedule and within budget.